LEGN Live signaler | Maksimer profitt med Getagraph.com

KJøP 20302 min ago

@ $52.08

Utstedt: 15 apr 2024 @ 20:17

Avkastning: -13.32%

Forrige signal: apr 15 - 19:41

Forrige signal: Selg

Avkastning: -1.02 %

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	954 343
Gjennomsnittsvolum	974 846
Markedsverdi	8.21B
EPS	$0 ( 2024-03-11 )
Neste inntjeningsdato	( $-0.240 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.35
ATR14	$0.0360 (0.08%)

Volum Korrelasjon

Lang: 0.12 (neutral)

Kort: -0.25 (neutral)

Signal:(41.274) Neutral

Legend Biotech Corp Korrelasjon

10 Mest positive korrelasjoner
AQST	0.804

10 Mest negative korrelasjoner
MACQU	-0.813
CFACU	-0.811

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Legend Biotech Corp Korrelasjon - Valuta/Råvare

0.45
( neutral )

0.41
( neutral )

0.00
( neutral )

0.47
( neutral )

0.77
( moderate )

-0.40
( neutral )

Legend Biotech Corp Økonomi

Annual	2023
Omsetning:	$285.14M
Bruttogevinst:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2023
Omsetning:	$285.14M
Bruttogevinst:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2022
Omsetning:	$117.01M
Bruttogevinst:	$51.64M (44.14 %)
EPS:	$-2.81

FY	2021
Omsetning:	$89.79M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.74

Financial Reports:

No articles found.

Legend Biotech Corp

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.